{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579041,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020916","name":"HUN-REN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003827","name":"National Research Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jid.2024.01.009","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:11:14Z","timestamp":1706530274000},"page":"1733-1742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Syk Inhibitor Entospletinib Abolishes Dermal\u2013Epidermal Separation in a Fully Human Ex\u00a0Vivo Model of Bullous Pemphigoid"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-0278","authenticated-orcid":false,"given":"Simon","family":"Vik\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-7233","authenticated-orcid":false,"given":"Kata P.","family":"Szilveszter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7820-683X","authenticated-orcid":false,"given":"Kamilla","family":"Koszor\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5093","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"S\u00e1rdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-1157","authenticated-orcid":false,"given":"Attila","family":"M\u00f3csai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2024.01.009_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.immuni.2013.02.018","article-title":"Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice","volume":"38","author":"Abram","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2024.01.009_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1126\/science.1079477","article-title":"Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk","volume":"299","author":"Abtahian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jid.2024.01.009_bib3","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jid.2024.01.009_bib4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Ba\u011fc\u0131","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2024.01.009_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jid.2024.01.009_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jid.2024.01.009_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jid.2024.01.009_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912876","article-title":"Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms","volume":"13","author":"Cole","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib9","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.01.009_bib10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3389\/fimmu.2019.00937","article-title":"Hematopoietic or osteoclast-specific deletion of Syk leads to increased bone mass in experimental mice","volume":"10","author":"Csete","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib11","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jid.2024.01.009_bib12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2024.01.009_bib13","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.4049\/jimmunol.1100341","article-title":"Deletion of Syk in neutrophils prevents immune complex arthritis","volume":"187","author":"Elliott","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib15","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.01.009_bib16","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2011-07-369041","article-title":"Dasatinib inhibits proinflammatory functions of mature human neutrophils","volume":"119","author":"Futosi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.01.009_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12507222","article-title":"An in\u00a0vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement","volume":"78","author":"Gammon","year":"1982","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jid.2024.01.009_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3899\/jrheum.140238","article-title":"A\u00a0phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-\u03b1 antagonist","volume":"41","author":"Genovese","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jid.2024.01.009_bib21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.2174\/15680266113139990094","article-title":"Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"13","author":"Gomez-Puerta","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jid.2024.01.009_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jid.2024.01.009_bib23","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2019.01454","article-title":"Proteases in pemphigoid diseases","volume":"10","author":"Hiroyasu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib24","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.27438","article-title":"Genetic deficiency of Syk protects mice from autoantibody-induced arthritis","volume":"62","author":"Jakus","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2024.01.009_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1242\/jcs.00241","article-title":"Analysis of the interactions between BP180, BP230, plectin and the integrin alpha6beta4 important for hemidesmosome assembly","volume":"116","author":"Koster","year":"2003","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.jid.2024.01.009_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2024.01.009_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12026-008-8028-y","article-title":"Complement and cutaneous autoimmune blistering diseases","volume":"41","author":"Lessey","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.jid.2024.01.009_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jid.2024.01.009_bib29","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.188.3.475","article-title":"Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid","volume":"188","author":"Liu","year":"1998","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2024.01.009_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2024.01.009_bib31","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ni1407","article-title":"Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs","volume":"7","author":"M\u00f3csai","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib32","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1073\/pnas.0401602101","article-title":"The immunomodulatory adapter proteins DAP12 and Fc receptor \u03b3-chain (FcR\u03b3) regulate development of functional osteoclasts through the Syk tyrosine kinase","volume":"101","author":"M\u00f3csai","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2024.01.009_bib33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1074-7613(02)00303-5","article-title":"Syk is required for integrin signaling in neutrophils","volume":"16","author":"M\u00f3csai","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2024.01.009_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jid.2022.12.016","article-title":"Neutrophil-specific Syk expression is crucial for skin disease in experimental epidermolysis bullosa acquisita","volume":"143","author":"N\u00e9meth","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib36","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.4049\/jimmunol.0904163","article-title":"Neutrophil functions and autoimmune arthritis in the absence of p190RhoGAP: generation and analysis of a novel null mutation in mice","volume":"185","author":"N\u00e9meth","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2018.00555","article-title":"Lineage-specific analysis of Syk function in autoantibody-induced arthritis","volume":"9","author":"N\u00e9meth","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib38","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jid.2017.05.017","article-title":"The Syk tyrosine kinase is required for skin inflammation in an in\u00a0vivo mouse model of epidermolysis bullosa acquisita","volume":"137","author":"N\u00e9meth","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1083\/jcb.200112113","article-title":"Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton","volume":"157","author":"Obergfell","year":"2002","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jid.2024.01.009_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.973702","article-title":"The relevance of complement in pemphigoid diseases: a critical appraisal","volume":"13","author":"Papara","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40261-016-0476-x","article-title":"Pharmacokinetics, pharmacodynamics, and safety of entospletinib, a novel pSYK inhibitor, following single and multiple oral dosing in healthy volunteers","volume":"37","author":"Ramanathan","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jid.2024.01.009_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.175","article-title":"In\u00a0vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib","volume":"3","author":"Rolf","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jid.2024.01.009_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals Syk as a key regulator of inflammation in experimental epidermolysis bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1523-1747.2000.00141.x","article-title":"Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes","volume":"115","author":"Schmidt","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2024.01.009_bib46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2040620716636542","article-title":"Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib","volume":"7","author":"Sharman","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jid.2024.01.009_bib47","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jid.2024.01.009_bib48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.1674","article-title":"Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid","volume":"204","author":"Shimanovich","year":"2004","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jid.2024.01.009_bib49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1046\/j.1523-1747.2002.01720.x","article-title":"Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin","volume":"118","author":"Sitaru","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib50","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.1365-2133.2000.03894.x","article-title":"High levels of interleukin-8, soluble CD4 and soluble CD8 in bullous pemphigoid blister fluid. The relationship between local cytokine production and lesional T-cell activities","volume":"143","author":"Sun","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2024.01.009_bib51","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib52","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid","volume":"10","author":"Tasanen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2024.01.009_bib53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41588-021-00803-4","article-title":"Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice","volume":"53","author":"Wang","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2024.01.009_bib54","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2024.01.009_bib55","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2024.01.009_bib56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X24000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T06:58:20Z","timestamp":1721372300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X24000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0022202X24000800"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2024.01.009","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Syk Inhibitor Entospletinib Abolishes Dermal\u2013Epidermal Separation in a Fully Human Ex\u00a0Vivo Model of Bullous Pemphigoid","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2024.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}